JP7504880B2 - Ａｌｋ２阻害剤の結晶形 - Google Patents

Ａｌｋ２阻害剤の結晶形 Download PDF

Info

Publication number
JP7504880B2
JP7504880B2 JP2021522993A JP2021522993A JP7504880B2 JP 7504880 B2 JP7504880 B2 JP 7504880B2 JP 2021522993 A JP2021522993 A JP 2021522993A JP 2021522993 A JP2021522993 A JP 2021522993A JP 7504880 B2 JP7504880 B2 JP 7504880B2
Authority
JP
Japan
Prior art keywords
compound
bmp
subject
fold
compositions described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512824A (ja
JP2022512824A5 (https=
Inventor
ベスーン、サラ
ディアス、クリスタ
エイ． エバンス、キャサリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keros Therapeutics Inc
Original Assignee
Keros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keros Therapeutics Inc filed Critical Keros Therapeutics Inc
Publication of JP2022512824A publication Critical patent/JP2022512824A/ja
Publication of JP2022512824A5 publication Critical patent/JP2022512824A5/ja
Priority to JP2024094803A priority Critical patent/JP2024107352A/ja
Application granted granted Critical
Publication of JP7504880B2 publication Critical patent/JP7504880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021522993A 2018-10-26 2019-10-25 Ａｌｋ２阻害剤の結晶形 Active JP7504880B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094803A JP2024107352A (ja) 2018-10-26 2024-06-12 Ａｌｋ２阻害剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751255P 2018-10-26 2018-10-26
US62/751,255 2018-10-26
PCT/US2019/058062 WO2020086963A1 (en) 2018-10-26 2019-10-25 Crystal forms of an alk2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094803A Division JP2024107352A (ja) 2018-10-26 2024-06-12 Ａｌｋ２阻害剤の結晶形

Publications (3)

Publication Number Publication Date
JP2022512824A JP2022512824A (ja) 2022-02-07
JP2022512824A5 JP2022512824A5 (https=) 2022-10-27
JP7504880B2 true JP7504880B2 (ja) 2024-06-24

Family

ID=70330555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522993A Active JP7504880B2 (ja) 2018-10-26 2019-10-25 Ａｌｋ２阻害剤の結晶形
JP2024094803A Pending JP2024107352A (ja) 2018-10-26 2024-06-12 Ａｌｋ２阻害剤の結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094803A Pending JP2024107352A (ja) 2018-10-26 2024-06-12 Ａｌｋ２阻害剤の結晶形

Country Status (8)

Country Link
US (1) US12071438B2 (https=)
EP (1) EP3870181B1 (https=)
JP (2) JP7504880B2 (https=)
CN (1) CN114269345B (https=)
AU (1) AU2019364631B2 (https=)
CA (1) CA3117695A1 (https=)
WO (1) WO2020086963A1 (https=)
ZA (1) ZA202103228B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519059A (ja) 2004-11-04 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なピラゾロ［１，５−α］ピリミジン
JP2013542257A (ja) 2010-11-10 2013-11-21 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
JP2016515119A (ja) 2013-03-14 2016-05-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20190055192A1 (en) 2004-06-07 2019-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
WO2006088972A2 (en) 2005-02-16 2006-08-24 The General Hospital Corporation Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
CA2631312A1 (en) 2005-11-29 2007-06-07 Nevada Cancer Institute Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
CN105503882B (zh) * 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CN109311889B (zh) 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
EP3615538B1 (en) 2017-04-27 2024-02-07 The Brigham and Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CU20200035A7 (es) 2017-11-24 2021-03-11 Novartis Ag Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
CN113366019B (zh) 2018-10-23 2024-08-27 科乐斯疗法公司 Alk2抗体及其使用方法
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
TWI870440B (zh) 2019-08-13 2025-01-21 美商纜圖藥品公司 活化素受體樣激酶抑制劑之鹽及晶體形式
ES3014839T3 (en) 2019-10-02 2025-04-25 Blueprint Medicines Corp Process for preparing an activin receptor-like kinase inhibitor
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
US20250034148A1 (en) 2021-11-02 2025-01-30 Keros Therapeutics, Inc. Methods of using alk2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519059A (ja) 2004-11-04 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なピラゾロ［１，５−α］ピリミジン
JP2013542257A (ja) 2010-11-10 2013-11-21 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
JP2016515119A (ja) 2013-03-14 2016-05-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法

Also Published As

Publication number Publication date
JP2022512824A (ja) 2022-02-07
JP2024107352A (ja) 2024-08-08
ZA202103228B (en) 2025-08-27
AU2019364631A1 (en) 2021-06-03
WO2020086963A1 (en) 2020-04-30
EP3870181A4 (en) 2022-07-20
AU2019364631B2 (en) 2025-05-01
US20210238185A1 (en) 2021-08-05
CN114269345B (zh) 2025-06-27
EP3870181A1 (en) 2021-09-01
US12071438B2 (en) 2024-08-27
EP3870181B1 (en) 2024-08-14
CA3117695A1 (en) 2020-04-30
CN114269345A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
JP7504880B2 (ja) Ａｌｋ２阻害剤の結晶形
JP5638961B2 (ja) Ｂｍｐシグナル伝達経路のインヒビター
JP6430383B2 (ja) 選択的ｂｍｐ阻害剤としての縮合複素環化合物
US10583143B2 (en) Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
US20160115167A1 (en) Bmp inhibitors and methods of use thereof
JP7179015B2 (ja) Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用
US20140038953A1 (en) Compositions and methods for cardiovascular disease
CN111164083B (zh) 用于抑制bmp信号传导的新型alk2抑制剂和方法
JP2017536411A (ja) Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
WO2016011019A1 (en) Compositions and methods for inhibiting bmp
JP2017514793A (ja) Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
JP2023516645A (ja) Ｔｅａｄ阻害剤としてのヘテロ二官能性分子
JP6909236B2 (ja) キナゾリン誘導体またはその塩およびそれを含む医薬組成物
AU2021352108B2 (en) Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2012157389A1 (ja) DOCK-Aサブファミリー分子によるRac活性化を制御する低分子化合物及びその用途
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
CN108658976B (zh) 一类新型吡唑并[4,3-c]吡啶-4(5)-酮布鲁顿激酶抑制剂
AU2007223865A1 (en) Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240612

R150 Certificate of patent or registration of utility model

Ref document number: 7504880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150